{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-019453","form_type":"8-K","ticker":null,"cik":"0001560241","company_name":"G1 Therapeutics, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.955624+00:00","generated_at":"2026-06-03T02:49:13.795910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"G1 Therapeutics Q1 2024: COSELA revenue $14.1M, net loss $10.2M, reaffirms 2024 guidance","bullets":["Net COSELA revenue $14.1M in Q1 2024; total revenue $14.5M, up from $12.9M YoY.","Net loss $10.2M ($0.20 per share) vs $27.6M ($0.53) in Q1 2023.","Cash and securities $65.2M; runway into Q3 2025.","Reaffirmed FY2024 COSELA net revenue guidance of $60-70M.","Phase 3 PRESERVE 2 final analysis expected late Q2 2024; Phase 2 trilaciclib+ADC data at ASCO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-019453","json":"https://secwatch.observer/filing/0001628280-24-019453.json","markdown":"https://secwatch.observer/filing/0001628280-24-019453.md","text":"https://secwatch.observer/filing/0001628280-24-019453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/0001628280-24-019453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/gthx-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:49:13.795910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ebb78e689939e022e3c59b2a3b7b14f1add04eb","claim":"G1 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $14.1 million in net product sales of COSELA, net income net loss for the first quarter of 2024 was $10.2 million, EPS $(0.20). Guidance reaffirmed.","evidence_excerpt":"G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/0001628280-24-019453-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$14.1 million in net product sales of COSELA"},{"label":"Net income","value":"net loss for the first quarter of 2024 was $10.2 million"},{"label":"EPS","value":"$(0.20)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}